Results for tag: "Frontotemporal Dementia"

Within the context of Central Nervous System (CNS) drugs, the Frontotemporal Dementia (FTD) market is focused on therapeutic interventions for managing the symptoms of this group of disorders, which affect the frontal and temporal lobes of the brain. CNS drugs encompass a wide range of medications designed to treat neurological and psychiatric conditions. For FTD, this includes medications that aim to alleviate behavioral disturbances, support cognitive function, and improve quality of life for patients. Since there is currently no cure for FTD, treatment is symptomatic and supportive, often involving off-label use of antipsychotics, antidepressants, and other agents used in various neurological disorders. Research within this market is aimed at understanding the pathophysiology of FTD to develop targeted therapies that can modify the disease's progression or affect its root cause. Companies active in the FTD market are engaged in the development of drug candidates that can potentially provide a disease-modifying effect or offer more effective symptom management. These include large pharmaceutical firms with diversified CNS portfolios, as well as smaller biotech companies specializing in neurodegenerative disorders. Some of these companies are Alector, Biogen, Lundbeck, and Eli Lilly and Company, which are involved in researching and developing treatments that address the pathological mechanisms underlying Frontotemporal Dementia or improve patient symptoms. Show Less Read more